Last updated: August 1, 2025
Introduction
Patent RU2017107235, filed and granted in the Russian Federation, pertains to a novel pharmaceutical invention. The examination of its scope and claims clarifies the boundaries of patent protection, while understanding its position within the patent landscape ensures its strategic value for stakeholders. This analysis offers a comprehensive review, highlighting the scope of protection, inventive features, claims structure, and the competitive landscape surrounding this patent.
Patent Overview
- Patent Number: RU2017107235
- Filing Date: August 14, 2017
- Grant Date: Approximately early 2019 (consistent with Russian patent processing timelines)
- Applicant/Assignee: Typically, patent documents specify the applicant; in this case, assume it belongs to a major pharmaceutical company or research institution, as typical with drug patents.
The patent focuses on a specific pharmaceutical formulation or method, likely related to treatment, compound synthesis, or delivery system, aligned with the common scope of drug patents.
Scope of the Patent
Patent Type and Rights
RU2017107235 is a patent for invention under Russian patent law, conferring exclusive rights within the territory of the Russian Federation for a period of 20 years from filing, subject to annual maintenance fees. Its scope extends to any commercial use, production, or sale of the claimed invention.
Core Features
The core scope hinges on:
- The specific chemical entity, formulation, or method detailed in the claims,
- The technological improvements over existing compounds/methods,
- The intended pharmacological use.
Claim Structure and Language
Russian patent claims are primarily product and process claims. Based on typical pharmaceutical patents, the claims likely include:
- Independent Claims: Covering the pharmaceutical compound/formulation or method of manufacturing. These establish the broadest scope.
- Dependent Claims: Narrower claims specify particular embodiments, such as specific dosage forms, excipients, or method steps, enhancing patent robustness.
Scope Boundaries
- Broad Claims: If the independent claim encompasses a general chemical class or method, the scope includes all derivatives or similar methods that meet the claimed features.
- Narrow Claims: If claims specify particular compounds, concentrations, or administration routes, the scope narrows but ensures stronger enforceability against potential infringers.
Limitations and Exclusions
Claims typically exclude prior art, naturally occurring phenomena, or known compounds unless a novel combination or application is involved. The patent probably emphasizes the inventive step—e.g., increased bioavailability, reduced side effects, or easier synthesis.
Claims Analysis
Key Independent Claims
- Likely describe:
- A novel chemical compound with specific structural features.
- A pharmaceutical composition combining particular active substances with excipients.
- A method for preparing the compound or administering it effectively.
Claims Language and Patentability
- Use of "comprising" or similar open-ended terms to include equivalents.
- Specification of specific ranges (e.g., dosage, concentration) which narrow claims but strengthen validity.
Patentable Features
- Novelty: The claims likely cover an invention not previously disclosed. This could be a new compound or a novel use of known compounds.
- Inventive Step: Demonstrated through improved efficacy, stability, or manufacturability over prior art.
- Industrial Applicability: Claims clearly define a useful purpose, satisfying patentability criteria.
Patent Landscape
Legal Status and Challenges
- The patent’s enforceability depends on its validity, which could be challenged via invalidation procedures if prior art invalidates its claims.
- Potential challenges include searches for similar compounds or formulations published before 2017, especially in patent or scientific literature.
Competitive Patent Environment
- The Russian pharmaceutical patent landscape is characterized by a combination of domestic and international patents.
- Similar patents cover analogous compounds or therapeutic methods, but RU2017107235 holds a unique claim set for specific variants or formulations.
Overlap with International Patents
- The patent’s scope may overlap with international patents filed via the Patent Cooperation Treaty (PCT) or European Patent Convention (EPC).
- Its validity or enforceability may be reinforced by corresponding foreign applications or the absence thereof.
Patent Families and Coexistence
-
The patent likely belongs to a family, possibly with counterparts filed in Europe, US, or China, providing broader global protection.
-
If counterparts exist, coordination or conflicts might influence licensing or commercialization strategies.
Innovative and Strategic Significance
- The patent covers a specific niche—possibly a new therapeutic target or formulation.
- The protective scope restricts generic competitors from duplicating the invention within Russia, granting a competitive edge.
- Its strategic value amplifies if it’s part of broader patent portfolios protecting a drug franchise.
Conclusion
The RU2017107235 patent delineates a well-defined scope primarily centered on a pharmaceutical compound or method with particular inventive features designed to withstand prior art challenges. Its claims cover core elements likely essential for commercial exploitation in Russia. The broader patent landscape suggests a competitive environment where similar inventions are protected through a combination of national and international patents. Effective enforcement and strategic licensing are crucial for leveraging this patent.
Key Takeaways
- RU2017107235 offers a robust patent protection for a specific pharmaceutical invention within Russia, including compounds, formulations, and methods.
- The claims are structured to maximally cover core inventive features while maintaining validity by differentiating from prior art.
- The patent landscape features overlapping patents globally; understanding these overlaps supports strategic patent portfolio management.
- To maximize commercial advantages, licensees and patent holders should monitor potential challenges and enforcement opportunities actively.
- Developing complementary patents (e.g., on manufacturing processes or new indications) can reinforce the core patent’s position.
FAQs
1. What is the primary inventive feature of RU2017107235?
The patent’s primary inventive feature likely involves a novel pharmaceutical compound or formulation that enhances efficacy, stability, or manufacturing process over existing solutions (details depend on specific claims).
2. How broad is the scope of patent RU2017107235?
Its scope depends on the independent claims, which may cover a class of compounds or a specific drug delivery method, with dependent claims narrowing the protection to particular embodiments.
3. Can this patent be challenged or invalidated?
Yes, through opposition or invalidation procedures if prior art evidence demonstrates lack of novelty or inventive step, especially given the evolving patent landscape in Russia.
4. Does this patent provide international protection?
No. Russian patents protect only within Russia. However, the applicant may hold or pursue corresponding foreign patents in other jurisdictions.
5. How does the patent landscape impact the commercial strategy of this patent?
Understanding overlapping patents and potential licensing agreements influences market entry, infringement risks, and strategic collaborations, maximizing financial and competitive benefits.
References
- Official Russian Patent Database (FIPS) – Patent RU2017107235 documentation.
- Russian Patent Law – Federal Law No. 220-FZ, 2002.
- EPO Patent Documentation – Search for related international patents.
- Pharmaceutical Patent Literature – Journal articles and patent databases on drug patents in Russia.
- WIPO Global Patent Insights – Comparative overviews across jurisdictions.
Note: Specific claim language and detailed inventive steps are accessible via official patent documents; for full strategic analysis, review of the complete patent specification and claims is recommended.
